Atorvastatin Treatment

Phase 2Small molecule

TThe Second Hospital of Anhui Medical University

Atorvastatin Treatment is one of 78 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Obstructive Sleep ApneaPhase 2

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Asmanex

Novartis

Phase 3

1 2

Foundayo

Eli Lilly

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 3

1 4

Farxiga

AstraZeneca

Phase 3

1 5

MS Contin

Lunesta

3 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 8

Ketalar

AAultman Health Foundation

Phase 3

2 9

Advil

KKenvue Brands

Phase 3

1 10

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Intracerebral Hemorrhage

NCT07088250

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Statins for Treatment of Primary Intracerebral Hemorrhage

Recruiting·TThe Second Hospital of Anhui Medical University·N/A·NCT07088250·264 enrolled

Obstructive Sleep Apnea1 trial

Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin

Terminated·UUniversity Hospital, Grenoble·Phase 2·NCT00669695·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Atorvastatin Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atorvastatin Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atorvastatin Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Hospital of Anhui Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe Second Hospital of Anhui Medical University

Atorvastatin Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Obstructive Sleep Apnea1 trial

References

Drug Info

Quick Facts

Related News